Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Sponsor: Johns Hopkins University
Summary
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-09-20
Completion Date
2026-09-01
Last Updated
2025-10-15
Healthy Volunteers
No
Interventions
Sildenafil
Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
Placebo
Oral pill placebo.
Locations (2)
Louisiana State University
New Orleans, Louisiana, United States
Johns Hopkins
Baltimore, Maryland, United States